Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
NCT04159155 · University Health Network, Toronto · PHASE2/PHASE3 · terminated · last registry update 2025-08-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low accrual” | – | Registry record, University Health Network, Toronto |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PARP2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-12Results posted on the registry: National Cancer Institute (NCI), Talazoparib + Temozolomide (NCT05142241)
- 2026-08-03Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-08-03Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-07-22Also stopped (terminated): Mayo Clinic, Abiraterone Acetate/Niraparib + Prednisone (NCT05689021)
- 2026-07-17Results posted on the registry: Memorial Sloan Kettering Cancer Center, Rucaparib + Nivolumab (NCT04624178)
- 2026-06-29Also stopped (terminated): University of Iowa, Niraparib + Dostarlimab (NCT04926324)
- 2026-06-17Results posted on the registry: National Cancer Institute (NCI), Olaparib (NCT03212274)
- 2026-06-11Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Abiraterone (NCT07641855)
- 2026-06-09Results posted on the registry: AstraZeneca, Bevacizumab + Durvalumab (NCT03737643)
- 2026-06-05Also stopped (withdrawn): University of Alabama at Birmingham, M4344+Niraparib + M4344+Niraparib (NCT04149145)
- 2026-06-04Results posted on the registry: Novartis Pharmaceuticals, Alpelisib + Olaparib (NCT04729387)
- 2026-06-03Results posted on the registry: University of Oklahoma, Bevacizumab + Niraparib (NCT05523440)
- 2026-06-03Also stopped (terminated): University of Oklahoma, Bevacizumab + Niraparib (NCT05523440)
- 2026-06-01Results posted on the registry: Allarity Therapeutics, 2X-121 600 mg + 2X-121 800 mg (NCT05571969)
- 2026-06-01Also stopped (terminated): Allarity Therapeutics, 2X-121 600 mg + 2X-121 800 mg (NCT05571969)
- 2026-05-29Results posted on the registry: Memorial Sloan Kettering Cancer Center, Olaparib + Pembrolizumab (NCT05203445)
- 2026-05-19Results posted on the registry: National Cancer Institute (NCI), Cisplatin + Gemcitabine (NCT01585805)
- 2026-05-15Results posted on the registry: Academic and Community Cancer Research United, Olaparib (NCT04042831)
- 2026-05-14Results posted on the registry: University of California, Davis, Niraparib + Niraparib Tosylate Monohydrate (NCT04030559)
- 2026-05-14Also stopped (terminated): University of California, Davis, Niraparib + Niraparib Tosylate Monohydrate (NCT04030559)
- 2026-05-06Results posted on the registry: Trisha Wise-Draper, Niraparib + Dostarlimab (NCT04313504)
- 2026-05-05Results posted on the registry: National Cancer Institute (NCI), Olaparib (NCT03317392)
- 2026-05-04Results posted on the registry: University of Colorado, Denver, Pembrolizumab + Olaparib (NCT05379972)
- 2026-05-01Results posted on the registry: GlaxoSmithKline, Niraparib + Pembrolizumab (NCT04475939)
- 2026-04-24Phase 3 first posted: Shanghai Municipal Hospital of Traditional Chinese Medicine, Tiaoshen Anti-cancer Granules + Placebo Granules (NCT07550205)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision